Have a feature idea you'd love to see implemented?
Let us know!
PCSA Processa Pharmaceuticals Inc
Price (delayed)
$0.88
Market cap
$2.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.83
Enterprise value
$80,291
Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a
Highlights
The EPS has soared by 79% YoY and by 10% from the previous quarter
PCSA's debt is down by 44% year-on-year and by 19% since the previous quarter
PCSA's net income is up by 47% YoY but it is down by 13% QoQ
Processa Pharmaceuticals's quick ratio has shrunk by 71% YoY and by 34% QoQ
Processa Pharmaceuticals's equity has decreased by 48% YoY and by 38% QoQ
Key stats
What are the main financial stats of PCSA
Market
Valuations
Earnings
Shares outstanding
3.27M
Market cap
$2.87M
Enterprise value
$80,291
Price to earnings (P/E)
N/A
Price to book (P/B)
0.77
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$11.53M
EBITDA
-$11.44M
Free cash flow
-$11.12M
Per share
Balance sheet
Liquidity
EPS
-$4.83
Free cash flow per share
-$3.39
Book value per share
$1.14
Revenue per share
$0
TBVPS
$1.51
Total assets
$4.94M
Total liabilities
$1.22M
Debt
$96,844
Equity
$3.72M
Working capital
$3.62M
Debt to equity
0.03
Current ratio
3.97
Quick ratio
2.37
Net debt/EBITDA
0.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-163.1%
Return on equity
-195.2%
Return on invested capital
-2,115.1%
Return on capital employed
-309.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCSA stock price
How has the Processa Pharmaceuticals stock price performed over time
Intraday
-3.3%
1 week
-16.55%
1 month
-37.59%
1 year
-88.93%
YTD
-86.85%
QTD
-35.77%
Financial performance
How have Processa Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$11.63M
Net income
-$11.53M
Gross margin
N/A
Net margin
N/A
PCSA's net income is up by 47% YoY but it is down by 13% QoQ
Processa Pharmaceuticals's operating income has increased by 47% YoY but it has decreased by 12% QoQ
Growth
What is Processa Pharmaceuticals's growth rate over time
Valuation
What is Processa Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.77
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 79% YoY and by 10% from the previous quarter
PCSA's P/B is 80% below its 5-year quarterly average of 3.8 and 36% below its last 4 quarters average of 1.2
Processa Pharmaceuticals's equity has decreased by 48% YoY and by 38% QoQ
Efficiency
How efficient is Processa Pharmaceuticals business performance
Processa Pharmaceuticals's return on invested capital has increased by 41% YoY and by 6% QoQ
Processa Pharmaceuticals's return on equity has decreased by 29% QoQ but it has increased by 24% YoY
The ROA has grown by 26% YoY but it has contracted by 25% from the previous quarter
Dividends
What is PCSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCSA.
Financial health
How did Processa Pharmaceuticals financials performed over time
Processa Pharmaceuticals's quick ratio has shrunk by 71% YoY and by 34% QoQ
The current ratio has dropped by 59% year-on-year and by 18% since the previous quarter
PCSA's debt is 97% smaller than its equity
Processa Pharmaceuticals's debt to equity has soared by 50% from the previous quarter and by 50% YoY
Processa Pharmaceuticals's equity has decreased by 48% YoY and by 38% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.